Evaluation and Comparison of the Seroprevalence of Hepatitis B and Hepatitis C Virus Infection in Patients Admitted to Clinics at the “Mogadishu, Turkey Recep Tayyip Erdogan Training and Research Hospital” in Somalia

Year 2021, Volume: 3 Issue: 3, 76 - 81, 14.10.2021

Öznur Sarı

https://doi.org/10.52827/hititmedj.950527

Abstract

Objective: To evaluate hepatitis B and hepatitis C serology findings and to determine the
current prevalence of those who had applied to the Turkish hospital in Mogadishu,
Somalia.

Material and Method: The demographic findings and hepatitis test results (HBsAg, antiHBs antibody, and anti-HCV) of the patients were recorded retrospectively from their files.

Results: A total of 152,266 patients, 75,903 (49.8%) male and 76,363 (50.2%) female,
with a mean age of 34 (31/61) years, were included in our study. 1,278 (1.9%) of 67,749
patients who were tested for anti-HCV were found to be positive. 27,208 patients (32.2%)
were found to have developed natural or vaccine immunity for HBV. It was found that those
with anti-HCV (+) were generally older than 55 years and that those with HBsAg (+) were
generally younger than 55 years [OR: 6.02 (5.28-6.87): 95%, CI].

Conclusion: In our study, it can be said that HBsAg and anti-HCV seroprevalence (8.2%
and 1.9%, respectively) in the Somalia population is still above desired levels. The fact
that anti-Hbs antibody levels are at 32.2% underscores the importance of the
development and popularization of vaccination programs.

Keywords

HBV, HCV, Seroprevalence, Somali

Somali'de Bulunan “Mogadişu Türkiye Recep Tayyip Erdoğan Eğitim ve Araştırma Hastanesi” Kliniklerine Başvuran Hastalarda Hepatit B ve Hepatit C Virüs Enfeksiyonu Seroprevalansının Retrospektif Olarak Değerlendirilmesi

Abstract

Amaç: Somali Mogadişu'daki Türk hastanesine başvuranların hepatit B ve hepatit C
seroloji bulgularını değerlendirmeyi ve mevcut prevalansının belirlenmesi.

Gereç ve Yöntemler: Hastaların demografik bulguları ve hepatit test sonuçları (HBsAg,
anti-HBs antikoru ve anti-HCV) dosyalarından geriye dönük olarak kaydedildi.

Bulgular: Çalışmamıza yaş ortalaması 34 (31/61) yıl olan 75.903 (%49,8) erkek ve
76.363 (%50,2) kadın olmak üzere toplam 152.266 hasta dahil edildi. Anti-HCV için test
edilen 67.749 hastanın 1.278'i (%1,9) pozitif bulundu. 27.208 hastanın (%32,2) HBV için
doğal veya aşı bağışıklığı geliştirdiği bulundu. Anti-HCV (+) olanların genel olarak 55
yaşından büyük, HBsAg (+) olanların ise genellikle 55 yaşından küçük olduğu [OR: 6,02
(5,28-6,87): %95, CI] bulundu.

Sonuç: Çalışmamızda Somali popülasyonunda HBsAg ve anti-HCV seroprevalansının
(sırasıyla %8,2 ve %1,9) halen istenilen seviyelerin üzerinde olduğu söylenebilir. Anti-Hbs
antikor düzeylerinin %32,2 düzeyinde olması, aşılama programlarının geliştirilmesinin ve
yaygınlaştırılmasının önemini vurgulamaktadır.

Keywords

HBV, HCV, Seroprevalans, Somali

References

• 1. Daw MA, Dau AA. Hepatitis C virus in Arab world: a state of concern. Scientific World Journal 2012; 719494.
• 2. Hassan-Kadle MA. The Diagnostic Challenges, Possible Etiologies and Lack of Researches of Hepatocellular Carcinoma in Somalia. Open J Gastroenterol 2017;07:115-123.
• 3. Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009;50:661-662.
• 4. Rossi C, Shrier I, Marshall L et al. Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees: a systematic review and meta-analysis. PLoS One 2012;7:e44611.
• 5. Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003;23:39-46.
• 6. World Health Organization, Organization. WH. Prevention and control of viral hepatitis infection: framework for global action 2012 https://apps.who.int/iris/handle/10665/130012 (erişim tarihi: 5.06.2021)
• 7. Ott JJ, Stevens GA, Groeger J, Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212-2219.
• 8. Centers for Disease Control and Prevention (CDC). Adverse childhood experiences reported by adults --- five states, 2009. MMWR Morb Mortal Wkly Rep 2010;59:1609-1613.
• 9. Museru O, Franco-Paredes C. Epidemiology and clinical outcomes of hepatitis B virus infection among refugees seen at a U.S. travel medicine clinic: 2005-2008. Travel Med Infect Dis 2009;7:171-174.
• 10. Museru OI, Vargas M, Kinyua M. Hepatitis B virus infection among refugees resettled in the U.S.: high prevalence and challenges in access to health care. J Immigr Minor Heal 2010;12:823-827.
• 11. Roberts H, Kruszon-Moran D, Ly KN et al. Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988-2012. Hepatology 2016; 63:388-397.
• 12. Hassan-Kadle MA, Osman MS, Ogurtsov PP. Epidemiology of viral hepatitis in Somalia: Systematic review and metaanalysis study. World J Gastroenterol 2018;24:3927-3957.
• 13. Lın X, Robinson N, Thursz M et al. Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: Review of disease progression. J Gastroenterol Hepatol 2005;20: 833- 843.
• 14. Ladep NG. Problem of hepatocellular carcinoma in West Africa. World J Hepatol 2014;6:783.
• 15. Yang JD, Mohamed EA, Aziz AOA et al. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol 2017;2:103-111.
• 16. Lemoine M, Thursz MR. Battlefield against hepatitis B infection and HCC in Africa. J Hepatol 2017;66: 645-654.
• 17. Kew MC. Epidemiology of hepatocellular carcinoma in subSaharan Africa. Ann Hepatol 2013;12:173-182.
• 18. Crocker-Buque T, Pollock AM. Appraising the quality of subSaharan African cancer registration systems that contributed to GLOBOCAN 2008: a review of the literature and critical appraisal. J R Soc Med 2015; 26;108:57-67.
• 19. Dalgard O, Mauss S. No strategy to meet the HCV epidemic. BMC Infect Dis 2014;14:S2.
• 20. Demsiss W, Seid A, Fiseha T. Hepatitis B and C: Seroprevalence, knowledge, practice and associated factors among medicine and health science students in Northeast Ethiopia. PLoS One 2018;13:e0196539.
• 21. Pérez-Romero M, Sánchez-Quijano A, Lissen E. Transmission of Hepatitis C Virus. Ann Intern Med 1990;113:411-412.
• 22. Belyhun Y, Maier M, Mulu A. Hepatitis viruses in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis 2016;16:761.
• 23. Averhoff FM, Glass N, Holtzman D. Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States. Clin Infect Dis 2012;55:10-15.
• 24. Bile K, Mohamud O, Aden C et al. The risk for hepatitis A, B, and C at two institutions for children in Somalia with different socioeconomic conditions. Am J Trop Med Hyg 1992;47: 357- 364.
• 25. Daw MA, Dau AA, Agnan MM. Influence of healthcare-associated factors on the efficacy of hepatitis C therapy. Scientific World Journal 2012;2012:580216.